Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: A lesson from two cases

Urologia Internationalis

Volumn 86, Issue 2, 2011, Pages 245-248

  Shablak, Alaaeldin ^a   O'Dwyer, Jackie ^a   Hawkins, Robert ^a   Board, Ruth ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Radiotherapy; Renal cell carcinoma; Sunitinib

Indexed keywords

ANALGESIC AGENT; SUNITINIB; ZOLEDRONIC ACID;

ADD ON THERAPY; ADRENAL METASTASIS; ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; ETHMOID SINUS; ETHMOID SINUS METASTASIS; EYE PAIN; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LOW BACK PAIN; LYMPH NODE METASTASIS; MALE; METASTASIS; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR PRURITUS; PANCREAS METASTASIS; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INDOLES; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PALLIATIVE CARE; PYRROLES; RADIATION-SENSITIZING AGENTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952985545     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321908     Document Type: Article

References (31)

1. McLaughlin JK, Lipworth L, Tarone RE: Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006; 33: 527-533. (Pubitemid 44511980)
2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. (Pubitemid 29368255)
3. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490. (Pubitemid 41770167)
4. Pagano S, Franzoso F, Ruggeri P: Renal cell carcinoma metastases: review of unusual clinical metastases, metastatic modes and patterns and comparison between clinical and autopsy metastatic series. Scand J Urol Nephrol 1996; 30: 165-172. (Pubitemid 26228176)
5. Yagoda A, Bander NH: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989; 44: 338-345. (Pubitemid 20008357)
6. Harris DT: Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983; 10: 422-430. (Pubitemid 14158611)
7. Yang JC, Childs R: Immunotherapy for renal cell cancer. J Clin Oncol 2006; 24: 5576-5583. (Pubitemid 46631338)
8. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410-2411. (Pubitemid 26264899)
9. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17.
10. Biswas S, Eisen T: Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 2009; 6: 478-487.
11. Shablak A, Hawkins RE, Rothwell DG, Elkord E: T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res 2009; 15: 6503-6510.
12. Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67: 1257-1264. (Pubitemid 46879093)
13. Patel PH, Chaganti RS, Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94: 614-619. (Pubitemid 43361889)
14. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. (Pubitemid 46630489)
15. Motzer RJ, Michaelson MD, Rosenberg J, et al: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-1887. (Pubitemid 47538608)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
17. Staehler M, Haseke N, Stadler T, et al: Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol 2010, Epub ahead of print.
18. Ljungberg B, Cowan NC, Hanbury DC, et al: EAU Guidelines on Renal Cell Carcinoma: the 2010 Update. Eur Urol 2010; 58: 398-406.
19. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. Lancet 2008; 372: 449-456.
20. Shepard RB, Garcia JA, et al: A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma (MCCRCC) refractory to prior sunitinib or bevacizumab. ASCO Meet Abstr 2008; 26 (suppl):5123.
21. Cho DC, Puzanov I, Regan MM, et al: Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targetedtherapy in patients with advanced renal cell carcinoma. J Immunother 2009; 32: 181-185.
22. Eichhorn ME, Strieth S, Dellian M: Antivascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Update 2004; 7: 125-138. (Pubitemid 38736065)
23. Sweeney CJ, Miller KD, Sledge GW Jr: Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003; 9: 24-29. (Pubitemid 36139252)
24. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969. (Pubitemid 27098025)
25. Rini BI, Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
26. Sandler A, Gray R, Perry MC, et al: Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
27. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
28. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62. (Pubitemid 40093472)
29. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-1175. (Pubitemid 43801134)
30. Senan S, Smit EF: Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007; 12: 465-477. (Pubitemid 46698724)
31. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I: Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 2006; 5: 232-234. (Pubitemid 46190386)